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Integrated DNA methylation analysis reveals a potential role
for ANKRD30B in Williams syndrome
Ryo Kimura 1, Roy Lardenoije2,3, Kiyotaka Tomiwa4,5,6, Yasuko Funabiki7,8, Masatoshi Nakata1, Shiho Suzuki1, Tomonari Awaya 1,
Takeo Kato4,9, Shin Okazaki5, Toshiya Murai8, Toshio Heike4,9, Bart P. F. Rutten 10 and Masatoshi Hagiwara1
Williams syndrome (WS) is a rare genetic disorder, caused by a microdeletion at the 7q11.23 region. WS exhibits a wide spectrum of
features including hypersociability, which contrasts with social deficits typically associated with autism spectrum disorders. The
phenotypic variability in WS likely involves epigenetic modifications; however, the nature of these events remains unclear. To better
understand the role of epigenetics in WS phenotypes, we integrated DNA methylation and gene expression profiles in blood from
patients with WS and controls. From these studies, 380 differentially methylated positions (DMPs), located throughout the genome,
were identified. Systems-level analysis revealed multiple co-methylation modules linked to intermediate phenotypes of WS, with
the top-scoring module related to neurogenesis and development of the central nervous system. Notably, ANKRD30B, a promising
hub gene, was significantly hypermethylated in blood and downregulated in brain tissue from individuals with WS. Most CpG sites
of ANKRD30B in blood were significantly correlated with brain regions. Furthermore, analyses of gene regulatory networks (GRNs)
yielded master regulator transcription factors associated with WS. Taken together, this systems-level approach highlights the role of
epigenetics in WS, and provides a possible explanation for the complex phenotypes observed in patients with WS.
Neuropsychopharmacology (2020) 0:1–10; https://doi.org/10.1038/s41386-020-0675-2
INTRODUCTION
Williams syndrome (WS, OMIM 194050), also referred to as
Williams–Beuren syndrome, is a rare genetic disorder caused by
the heterozygous deletion of 26–28 genes at 7q11.23, occurring in
~1 of 10,000 individuals [1]. The disorder is well known for
distinctive symptoms encompassing physical and cognitive features
and abilities, including characteristic facial features, cardiovascular
abnormalities, endocrine imbalances, and intellectual disability [1].
In particular, hypersociability and over-friendliness to strangers, so
called “cocktail party” personality, have received considerable
attention [1, 2]. Such hypersocial behavior seems to be opposite
to autism spectrum disorders (ASD), which are characterized by
reduced interest in social stimuli and genetic heterogeneity [2].
Therefore, studying WS is expected to illuminate genes and
pathways relevant to social behavior [2]. Several attempts to
identify the functions of deleted genes have suggested that GTF2I is
implicated in behavioral and/or cognitive abnormalities [3].
However, this does not explain the phenotypic variability observed
among WS patients, and genes related to neuropsychiatric features
such as hypersociability remains largely unknown.
Epigenetic mechanisms such as DNA methylation or histone
modification have been implicated in an array of neuropsychiatric
disorders, and thus might mediate social behavior [4, 5]. In
particular, DNA methylation significantly modifies transcriptional
regulation by altering transcription factor binding sites and
chromatin accessibility [6]. Accumulating evidence indicates that
altered DNA methylation in the blood, for example, in the gene
encoding the oxytocin receptor, is associated with social
behavior, implying that epigenetic effects on social behavior
are detectable even in peripheral blood [7]. Intriguingly, in WS,
several genes that are deleted from 7q11.23 are linked to
epigenetic regulation [8]. For example, BAZ1B, BCL7B, and
WBSCR22 are implicated in chromatin remodeling [9–11].
However, the potential role of DNA methylation in WS is poorly
characterized. To date, only one pioneering study has reported a
potential role of DNA methylation in WS, though that cohort was
limited [8]. Therefore, larger studies based on multiple experi-
mental approaches are needed to elucidate the role of DNA
methylation in WS.
We used a relatively large sample of WS patients and multiple
methods to address this need. We used robust methylome-
wide measurement methods, and employed weighted gene co-
methylation network analysis (WGCNA), an unbiased, systems
biology approach widely used to elucidate underlying biological
mechanisms [12]. Furthermore, we integrated methylation
and gene expression profiles using samples from the same
individuals to construct gene regulatory networks (GRNs) and
identify master regulator transcription factors related to WS [13].
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Together, our findings provide novel biological insights into the
role of epigenetics in WS.
MATERIALS AND METHODS
Samples and assessments
Ninety WS patients were recruited from each pediatric neurology
department (Kyoto University Hospital, Osaka City General
Hospital, and Todaiji Ryoiku Hospital for Children) through the
WS family support group in Japan. Diagnosis of WS was
established by fluorescent in situ hybridization (FISH). Thirty-four
healthy individuals as controls were recruited from the general
community through advertising. Controls were healthy people
without a current or previous diagnosis of a psychiatric disorder,
and had a negative family history for WS. Functional behavior was
assessed according to Japanese versions of the Child Behavior
Checklist for ages 6–18 (CBCL) or the Adult Behavior Checklist
(ABCL) [14]. Social functions were evaluated using the Social
Responsiveness Scale-2 (SRS-2); total T-scores of 59 or less
indicated no clinically significant concerns in social functioning,
whereas 60–65 indicated mild to moderate deficits in social
interaction [15]. T-scores were determined for both behavior and
social function, and the questionnaires for patients were
completed by their parents. All participants were Japanese, with
no history of use of psychotropic medications, did not smoke, and
had not received any medication for at least three months before
the collection of the blood samples. Whole-blood samples were
collected in EDTA tubes. Genomic DNA was extracted with the
QIAamp DNA Blood Midi Kit (Qiagen, Tokyo, Japan) and treated
with RNase A (Qiagen) to remove potential RNA contamination.
DNA quality was assessed using a NanoDrop 2000 spectrophot-
ometer (Thermo Fisher Scientific, Yokohama, Japan) and with
an Agilent 2200 TapeStation (Agilent Technologies, Tokyo, Japan).
All blood samples were collected on the same day as clinical
assessments. All patients were confirmed to have typical 7q11.23
deletions based on genomic quantitative PCR as previously
described [16]. This study was approved by institutional ethics
committees at each participating institution. Written informed
consent was obtained from all participants and/or their parents
according to the Declaration of Helsinki. Detailed demographics
are provided in Supplementary Table S1.
Genome-wide DNA methylation profiling
Genome-wide DNA methylation profiling was conducted on blood
samples from 34 WS patients and 34 controls. Genomic DNA was
bisulfite-converted using the EZ-96 DNA Methylation Kit (Zymo
Research, Irvine, CA, USA). DNA methylation was assessed using
Illumina Infinium HumanMethylation450 BeadChip (Illumina, San
Diego, CA, USA). Data quality control and analysis were performed
with ChAMP version 2.6.4 [17]. Briefly, probe filtering was applied
to remove probes that failed to hybridize with a detection p-value
(p) above 0.01 in one or more samples and with a bead count of
<3 in 5% of samples; then, probes on sex chromosomes, those
containing single-nucleotide polymorphisms, and non-specific
binding probes were also filtered out [17]. The β-value distribu-
tions of the two types of probes were corrected using Beta
Mixture Quantile dilation [18]. After quality control, 408,525 CpG
probes were retained for further analysis. The singular value
decomposition (SVD) method was used to identify batch effects
and the ComBat method was used to correct for their
effects related to age, sex, array slide, and position. Cell-type
composition was estimated using the Houseman algorithm to
adjust for potential differential cellular heterogeneity in blood [19].
Differentially methylated positions (DMPs) with a false discovery
rate (FDR) < 0.05 and β-value difference >0.1 were identified using
the R package Limma [20]. Differentially methylated regions
(DMRs) were identified using the DMRcate R package with the
default settings [21]. DMRcate is based on tunable kernel
smoothing of the differential methylation signal. DMRs were
defined as regions with a maximal 1000 bp containing two or
more CpGs. Multiple testing correction was performed by the
Benjamini–Hochberg procedure for FDR [22]. The gometh function
of the R package missMethyl was used to analyze gene ontology
(GO) enrichment in the original list of 408,525 CpG sites [23].
Weighted gene co-methylation network analysis (WGCNA)
The WGCNA R package was applied to the entire methylation
dataset to identify co-methylation modules [12]. Briefly, to
construct modules, the soft-thresholding power was set to 12 to
maximize scale-free topology model fit as it plateaued above
0.9. The initial module assignments were determined by using a
dynamic tree-cutting algorithm with deepSplit = 4, minModu-
lesize = 100, and dthresh = 0.2. The methylation profile of
each module was summarized using the first principal compo-
nent (the module eigengene). Module eigengenes were then
analyzed for correlation with sample traits. Genes with the
highest module membership values were considered hub
genes. Modules were characterized by GO using Enrichr [24].
Details of disease enrichment analyses are provided in the
Supplemental Data.
Pyrosequencing
Pyrosequencing was performed on the samples from the methyla-
tion set (34 WS patients and 34 controls) as well as the complete
WS set (90 WS patients). DNA was bisulfite-converted using the
EpiTect Fast DNA Bisulfite Kit (Qiagen) and amplified by PCR using
the PyroMark PCR kit (Qiagen). Primers were designed using
PyroMark Assay Design Software 2.0 (Qiagen) and are listed in
Supplementary Table S2. PCR conditions consisted of initial
denaturing at 95 °C for 15min; 45 cycles of 94 °C for 30 s, 56 °C
for 30 s, and 72 °C for 30 s; and final extension at 72 °C for 10min.
Pyrosequencing was performed on the PyroMark Q96 ID system
with Gold Q96 Reagents (Qiagen). Methylation at each CpG site was
analyzed with PyroMark Q96 software (Qiagen). Mann–Whitney U
test was used for significance test.
Correlation analysis
DNA methylation was compared between blood samples and
brain tissues using the Blood Brain DNA Methylation Comparison
Tool (https://epigenetics.essex.ac.uk/bloodbrain/ [25]). Correla-
tions between DNA methylation and age were assessed based
on the Spearman’s correlation coefficient.
Enhancer linking by methylation/expression relationships (ELMER)
analysis
Using the ELMER R package (version 2.6.1) in supervised
mode, the methylation and expression data were integrated to
investigate GRNs and identify related master regulator transcrip-
tion factors [13]. Briefly, for this analysis the processed methylation
data β-values, as described above, were used, combined with
published expression data [16]. More details are provided in
the Supplemental Data.
Availability of data and materials
DNA methylation data are available at NCBI Gene Expression
Omnibus (https://www.ncbi.nlm.-nih.gov/geo/) under accession
number GSE119778. The code used to analyze the data is available
from the corresponding author upon reasonable request.
RESULTS
Genome-wide DNA methylation profiles
An overview of the study design is shown in Fig. 1a. The
methylation set was balanced to ensure no significant differ-
ences in age and sex between WS patients and controls. Total
T-scores on the SRS-2 were significantly higher in WS patients
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than in controls, and profiles based on the CBCL/ABCL were also
significantly more severe, whereas changes in the social motivation
subscale were not significant (Supplementary Table S1).
We investigated DNA methylation differences between WS
patients and controls using methylation arrays. After adjusting for
possible confounding factors, multidimensional scaling plots clearly
separated WS patients and controls (Supplementary Fig. S1). SVD
revealed that the first principal component (PC) was significantly
associated with the study groups (Supplementary Fig. S1). In
addition, white blood cell proportions were estimated using the
Houseman method [19]. We found that the number of B cells, CD4+
T cells, and granulocytes was significantly different between patients
and controls (Supplementary Fig. S2). We then adjusted for the
estimated cell-type proportions using linear regression models. We
identified 380 DMPs with an FDR < 0.05 and β-value difference >0.1
(Supplementary Table S3), with top-scoring sites located in or near
ZNRF2, FAM69A, LOC100101938, NTN1, ANKRD30B, and ZNRF3
(Table 1A). The corresponding Manhattan plot showed that these
positions were distributed across the genome (Fig. 1b). Global
methylation status of DMPs indicated that WS patients exhibited
significantly higher methylation levels than controls (Supplementary
Fig. S3). DNA methylation differences at each position within
the deleted region were small and below 0.1 (Supplementary
Table S4). GO analysis of biological process (Supplementary Fig. S4
and Supplementary Table S5) suggested that hypermethylated
sites were significantly enriched in homophilic cell adhesion
(p= 4.05E−8) and cell–cell adhesion via plasma membrane
(p= 1.93E−6). In contrast, hypomethylated sites were enriched for
protein localization to membrane (p= 2.16E−4) and negative
regulation of adenylate cyclase (p= 2.16E−4).
Apart from individual CpG sites, we next sought to identify
DMRs spanning multiple CpG probes using DMRcate. HOXA2 and
CRISP2 were identified, for which the Stouffer’s p-values were
4.90E−25 and 4.18E−20, respectively (Table 1B, Supplementary
Table S6). Of particular interest, ANKRD30B was one of the most
significant DMRs, with a Stouffer’s p-value of 2.28E−18 (Table 1B)
and containing top-scoring DMPs (Table 1A).
Identification of co-methylation modules related to WS
To acquire a systems-level understanding of the relationship
between DNA methylation and WS, we analyzed correlation
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Fig. 1 Genome-wide DNA methylation profiles of WS patients and control individuals. a Overview of the study. b Manhattan plot showing
chromosomal locations of −log10 (p-values) for the association at each locus. Top DMPs in the methylation set are annotated by gene symbols.
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identified 16 co-methylation modules that could be described by
module eigengenes (Supplementary Fig. S5). Five of these were
found to be significantly correlated with WS with an FDR < 0.05
and absolute R > 0.45 (Fig. 2a, b). Of these, module M8 was the
most strongly correlated (R= 0.61 and FDR= 4.19E−8; Fig. 2b).
Notably, three of these modules (M3, M8, and M14) were
significantly correlated with total T-scores on the SRS-2 and
attention problems on the CBCL/ABCL (Fig. 2b). In contrast, M6
was significantly correlated with age, a known confounding factor,
and hence was excluded from subsequent analysis. M3, M5, and
M8 contained genes that were hypermethylated in WS patients,
whereas those of M14 were hypomethylated (Fig. 2c–f). Together,
we successfully identified multiple WS-associated modules, which
may potentially link to their phenotypes.
To explore the possible link between WS-associated modules
and genetic findings in neuropsychiatric disorders, we performed
gene list enrichment analysis (Supplementary Table S7). The M3
module was significantly enriched for intelligence- and Alzheimer
disease-associated genes (FDR= 2.9E−2 and 6.2E−15, respec-
tively; Fig. 2g). The M5 module was significantly enriched for
ADHD (FDR= 1.6E−4), whereas M8 and M14 were significantly
enriched in differentially methylated genes previously identified in
WS (FDR= 2.1E−12 and 9.0E−5, respectively). To further investi-
gate the biological function of each module, GO was analyzed
using Enrichr (Fig. 2h, Supplementary Table S8). Remarkably, M8
was highly enriched in genes associated with neurogenesis,
central nervous system development, and synapse assembly. The
top 15 connected genes in this module as hubs included
ANKRD30B, WBSCR22, and PCDHB18 (Fig. 2i, Supplementary
Table S9). M3 was enriched for genes related to the detection of
chemical stimuli involved in the sensory perception of smell, with
SNRNP70 and TRIM40 as top hub genes (Supplementary Fig. S5).
M5 was enriched in genes related to lipoprotein and cholesterol,
with PDE9A and FBN3 as hub genes (Supplementary Fig. S5).
M14 was enriched in genes that regulate sodium levels and
cardiac ventricle formation, with RGS2 and DUSP26 as hub genes
(Supplementary Fig. S5). Taken together, these findings suggest
that M8 might be disease-specific, thereby providing potential
insight into the complex neuropsychiatric phenotypes of WS.
ANKRD30B methylation and expression in WS
We then investigated ANKRD30B in M8, as it was identified in
both conventional and systems-level approaches (Figs. 2i and
3a). Accordingly, ANKRD30B was pyrosequenced in the methyla-
tion set using probes against transcription start sites, as such
sites are more likely to affect the expression of downstream
genes or phenotypes. We found that cg13266435 and
cg21293934, both of which are located in the ANKRD30B
promoter, were hypermethylated in WS patients (p < 1.4E−9
and p < 1.2E−7, respectively; Fig. 3b, c). Other CpG sites were
also significantly hypermethylated (Supplementary Fig. S6). As it
is known to have a clear effect on DNA methylation, we assessed
whether age would influence DNA methylation of ANKRD30B in
WS. Using the complete WS set consisting of 90 patients with an
age range of 1–43 years old, we found that age was not
significantly correlated with ANKRD30B methylation levels at
both at either cg13266435 or cg21293934 (Fig. 3d, e). In addition,
we examined the effects of sex on DNA methylation in ANKRD30B
within WS patients. Although ANKRD30B methylation levels at
cg13266435 were not significantly different between male
and female patients, methylation levels at cg21293934 were
weakly significantly different (p= 0.54 and p= 0.04, respectively;
Supplementary Fig. S7).
Next, the methylation state of each CpG site in ANKRD30B was
compared between blood and brain tissues using the Blood Brain
DNA Methylation Comparison Tool [25]. Ten out of eleven CpG
sites identified in the blood samples were significantly and
positively correlated with both the prefrontal cortex (PFC) and the
superior temporal gyrus (STG) regions (R= 0.33–0.66 and R=
0.39–0.64, respectively; Fig. 3f). It is known that both PFC and STG
Table 1. (A) A list of genome-wide significant differentially methylated positions (DMPs). (B) List of genome-wide significant differentially methylated
regions (DMRs).
(A) CpG site Gene symbol Chr. Feature β in WS β in
control
Δβ p-value
cg24152511 NA chr1 IGR 0.28 0.40 −0.12 3.19E−09
cg08549335 ZNRF2 chr7 Body 0.20 0.35 −0.15 3.34E−09
cg11310341 NA chr12 IGR 0.55 0.37 0.18 5.54E−09
cg08893087 FAM69A chr1 Body 0.57 0.69 −0.12 5.85E−09
cg15915602 NA chr2 IGR 0.83 0.68 0.15 6.98E−09
cg16519217 NA chr6 IGR 0.52 0.64 −0.12 8.11E−09
cg15509177 LOC100101938 chr13 TSS200 0.72 0.55 0.17 1.10E−08
cg01862363 NTN1 chr17 Body 0.67 0.53 0.14 1.26E−08
cg21293934 ANKRD30B chr18 TSS200 0.65 0.45 0.20 1.37E−08
cg07127410 ZNRF3 chr22 Body 0.50 0.61 −0.11 1.43E−08
(B) Chr. Start (bp) End (bp) CpG FDR Stouffer Mean β Overlapping
promoters
chr7 27141388 27144595 30 1.47E−44 4.90E−25 −0.02 HOXA2
chr6 49681178 49681774 9 1.97E−39 4.18E−20 0.09 CRISP2
chr6 3848218 3850738 34 1.11E−29 8.18E−19 0.02 FAM50B
chr6 28058715 28059208 9 2.23E−36 1.13E−18 0.06 ZSCAN12P1
chr18 14747036 14748439 14 1.80E−62 2.28E−18 0.11 ANKRD30B
IGR intergenic region, Body gene body, TSS200 0–200 bases upstream from the transcriptional start site, FDR false discovery rate, Stouffer Stouffer’s p-value,
NA not available.
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Fig. 2 Co-methylation modules associated with WS. a Correlation between module eigengenes and WS. Colored bars represent significant
correlations with an FDR < 0.05 and an absolute R > 0.45. b Heatmap of positive (red) or negative (blue) correlations between modules and
traits. SRS-2 Social Responsiveness Scale Second Edition, Total total T-score, SM social motivation, CBCL/ABCL Child/Adult Behavior Checklist,
IP internalizing problems, EP externalizing problems, TP thought problems, AP attention problems. c–f Module eigengene values (y axis) for
c M3, d M5, e M8, and f M14 in individual samples (x axis). g Enrichment analysis of disease-associated genes. Gene lists were compiled from
the literature (Supplementary Table S7). ASD autism spectrum disorder, ADHD attention-deficit hyperactivity disorder, IQ intelligence quotient,
AD Alzheimer disease, DM diabetes mellitus, hyper and hypo hypermethylated and hypomethylated genes in WS. h Top four biological
processes associated with each module. GO terms are ranked based on the Enrichr combined score. i Co-methylation networks among hub
genes in M8. The FDR < 0.05 are shown in parentheses.
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regions are related to social function. Recently, multiple studies
have shown that DNA methylation at specific loci can be
influenced by sequence variations, and such sites are called
methylation quantitative trait loci (meQTL) [26]. However, we
found that ANKRD30B sites were not associated with meQTL in the
developing brain (Supplementary Table S10) [25].
Furthermore, we examined expression of ANKRD30B in frontal
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GSE128841) [3]. Although the sample size was small, we found
that ANKRD30B was significantly downregulated in WS patients
compared to controls (Fig. 3g). Together, these results suggest
that ANKRD30B hypermethylation might occur not only in the
blood but also in the brain.
Integrative analysis of gene expression and methylation
We next investigated possible changes in the DNA methylation/
demethylation machinery in WS. DNA methylation patterns are
established and maintained by DNA methyltransferases (DNMTs)
such as DNMT1, DNMT3A, and DNMT3B, whereas the ten-eleven
translocation (TET) family including TET1, TET2, and TET3 mediates
active DNA demethylation [6]. Epigenetic regulators (DNMT1,
DNMT3A, DNMT3B, TET1, TET2, and TET3) expression levels were
determined using our previously published gene expression data
(GSE89594) [16]. Interestingly, we found that DNMT1 was signifi-
cantly upregulated, whereas TET2 was significantly downregulated
in WS patients (Fig. 4a). These findings may provide clues to further
our understanding of the mechanisms behind aberrant methylation
in WS.
Finally, to investigate GRNs and related master regulator
transcription factors, we performed ELMER analysis with 141,731
distal probes. After the formation of potential probe–gene pairs,
18 of the hypermethylated probe–gene pairs and 62 of the
hypomethylated probe–gene pairs were found to be significantly
associated (Supplementary Table S11). The top GO biological
processes associated with the genes in these pairs are shown in
Fig. 4b; Supplementary Table S12. Notably, the hypermethylated
probe–gene pairs were enriched for dorsal aorta morphogenesis
and heart development. In contrast, the hypomethylated
probe–gene pairs were enriched in fructose metabolic process
and adherens junction. Subsequent motif enrichment analysis
identified no motifs associated with the hypermethylated
probes, whereas 44 motifs were enriched with the hypomethy-
lated probes (Supplementary Table S13), thus only the latter
were used for the identification of upstream transcription factors.
The top three transcription factors associated with the hypo-
methylated probes in WS were BCL11A (p= 1.29E−04), TFCP2L1
(p= 1.68E−03), and MESP2 (p= 1.97E−03; Fig. 4c).
DISCUSSION
The primary aim of this study was to identify DNA methylation
profiles that are associated with WS using peripheral blood. Among
several co-methylated modules identified, ANKRD30B (ankyrin repeat
domain-containing protein 30B) was found to be significantly
hypermethylated in patients, both by conventional and systems-
level analysis. Importantly, we found that ANKRD30B methylation
status in blood samples was not only similar to that in brain tissues,
but also elevated over a wide age range. Furthermore, we identified
master regulator transcription factors related to WS by integrating
methylation and gene expression profiles.
ANKRD30B is located at 18p11.21, and is known to be more
abundantly expressed in the brain than in blood [27]. In our study,
we could not detect any expression of the ANKRD30B gene in the
blood samples from both WS patients and controls. Although its
biological function is unclear, a recent study showed that it is
hypermethylated and downregulated in the brains of Alzheimer
disease patients [28]. This result might provide a epigenetic
insight into the observation that some WS patients exhibit early
cognitive decline like senile dementia [1]. Interestingly, sequence
similarity analysis of ANKRD30B among species revealed that only
ANKRD30B of gorilla and vervet-AGM are highly conserved with
humans throughout evolution with high confidence (Supplemen-
tary Table S14). Thus, ANKRD30B might have a critical role in
unique brain functions in higher primates, although this requires
experimental validation. Other top DMRs, such as HOXA2 and
CRISP2, also showed an association with disease phenotypes. The
transcriptional regulator HOXA2 (Homeobox A2) controls the
development of some parts of the face and middle ear [29],
whereas CRISP2 (Cysteine-rich secretory protein 2), also identified
as a hub gene in M8, is a testicular sperm protein proposed to be
involved in sperm-egg interaction [30]. CRISP2 is differentially
methylated in atherosclerotic patients, suggesting an association
with cardiovascular diseases [31]. Although we found that nine
CpG sites in CRISP2 identified in blood were significantly and
positively correlated with both the PFC and STG regions
(Supplementary Fig. S8), the expression levels of CRISP2 in the
brain from WS patients remain unknown. As WS patients present
characteristic facial features and hearing problems such as
hyperacusis, and are commonly hypertensive [1], these data
collectively highlight aberrant DNA methylation as a potential
underlying cause.
Unlike conventional methods, WGCNA mines gene networks
constructed by the hierarchical clustering of methylated sites [12].
Four modules identified in this manner (M3, M5, M8, and M14)
were found to be associated with WS. Although blood samples
were tested, GO analysis indicated that M8 encompasses genes
associated with neuronal development. In addition, M3 was
associated with olfactory sensation, intelligence, and Alzheimer
disease. Although olfactory impairment has been linked to
prodromal Alzheimer disease [32], olfactory functions in WS are
still poorly characterized compared to visual and hearing issues.
Meanwhile, M5 was associated with metabolic processes such as
lipoprotein and cholesterol, which might provide clues as to why
adults with this disease tend to develop obesity [1]. Therefore, our
identified co-methylation modules have the potential to con-
tribute to understanding the epigenetic basis of WS phenotypes.
Cardiovascular abnormalities like supra valvular aortic stenosis
seen in WS are considered to be caused by the deletion of elastin
[1]. However, the involvement of epigenetic factors has been
suspected because not all WS patients present with cardiac
abnormalities. Our results showed that the hypermethylated
probe–gene pairs were associated with dorsal aorta morphogenesis
and heart development, further supporting the idea that epigenetic
events contribute to the cardiovascular abnormalities seen in WS.
Furthermore, our approach revealed that an unexpected
phenotype that could be related to WS. Recently, Burkitt lymphoma,
Fig. 3 Targeted pyrosequencing of ANKRD30B and correlation between ANKRD30B methylation in the blood and brain. a Scatter
plots with loess lines showing ANKRD30B methylation in WS patients and control individuals. Data points are methylation levels for each
probe in individual samples based on methylation array. b, c Validation of selected CpG sites in ANKRD30B. Box plots represent
methylation levels as measured by pyrosequencing. Groups in the methylation set (34 WS patients and 34 controls) were compared by
Mann–Whitney U test. d, e Effects of age on DNA methylation in ANKRD30B using the complete WS set (90 WS patients). Spearman’s
correlation coefficient (R) and p-values are indicated. f Correlation of the methylation status of CpG sites in ANKRD30B between blood
samples and PFC and STG tissues in the brain. Pearson’s correlation coefficient (R) and p-values are indicated. TSS1500 200–1500 bases
upstream from the transcriptional start site, TSS200 0–200 bases upstream from the transcriptional start site. g Differential expression of
ANKRD30B. ANKRD30B was significantly downregulated in WS patients compared to controls in frontal cortex. RNA-Seq data (GSE128841)
were obtained from Barak et al. [3]. DESeq was used for differential expression analysis. Pink dots indicate WS patients (n= 3), whereas
blue dots indicate controls (n= 3).
Integrated DNA methylation analysis reveals a potential role for. . .
R Kimura et al.
7
Neuropsychopharmacology (2020) 0:1 – 10
a highly aggressive B-cell non-Hodgkin type, has been gaining
interest in terms of its relationship with WS [33]. We found that B
cells were significantly more prevalent in patients than in controls.
This result supports the concept that abnormal B cell counts in WS
patients can result in lymphoma. However, it should be noted that
cell-type compositions in this study were estimated by the
Houseman algorithm. Therefore, further study will be needed to
confirm with hematologic assessments using cell staining and to
search for unidentified mutations in WS.
DNA methylation is influenced by genetic, environmental and
technical factors such as ethnicity, age, smoking status, and
medication. Thus, the ability to replicate findings of past
methylation studies might be limited, even if some of these
factors are controlled. The present study primarily analyzed
Fig. 4 Gene expression profiles of DNA methylation regulators and gene regulatory networks related to WS. a Epigenetic regulators
(DNMT1, DNMT3A, DNMT3B, TET1, TET2, and TET3) expression levels were determined by our published data (GSE89594) [16]. Red indicates
WS patients (n= 32), whereas blue indicates controls (n= 30). The FDR < 0.05 was considered significant. b Top biological process terms
associated with hyper- and hypomethylated probe–gene pairs. GO terms are ranked based on the Enrichr combined score. c Identification
of master regulator transcription factors related to WS. All transcription factors are ranked by their correlation with methylation changes of
distal probes of a PATZ1-binding motif, which BCL11A binds. Colored dots indicate the top three most anti-correlated transcription factors
(BCL11A, TFCP2L1, and MESP2). The vertical dotted line indicates the 5% highest ranked transcription factors. FDR false discovery rate,
TF transcription factor.
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Japanese adolescent and young adult individuals, whereas the
previous study examined children approximately 5–6 years of age
and mainly of European ancestry [8]. Despite these differences,
the top DMPs at or near ANKRD30B, NTN1, RFPL2, and PRDM9
overlap those identified previously in children with WS [8]. NTN1 is
implicated in axonal outgrowth and guidance, and thus is involved
in the development of the nervous system [34]. RFPL2 is abundantly
expressed in the developing human neocortex and during the onset
of neurogenesis [35], whereas PRDM9 positions double-strand
breaks during homologous recombination [36]. Our findings extend
those of the previous study and provide robust evidence that
alterations in DNA methylation patterns occur in WS.
Gene expression levels are strongly influenced by the methylation
levels at distal regulatory elements, notably enhancers [37]. The
ELMER analysis exploits the interplay between DNA methylation and
transcription factor binding at distal regulatory sites to identify
potential master regulator transcription factors that may help
explain how microdeletion has such widespread functional con-
sequences. Therefore, identifying master regulator transcription
factors provides insight into complex biological outcomes through
the regulation of multiple genes, and these transcription factors
could serve as targets for the development of novel therapeutic
approaches [38]. Through ELMER analysis, we identified BCL11A as a
potential upstream master regulator transcription factor. Interest-
ingly, this gene encodes subunits of SWI/SNF chromatin-remodeling
complexes, known to be involved in intellectual disability and
previously identified as hub genes in an upregulated module in WS
[16]. A causal link between aberrant methylation throughout the
genome and deletion of 7q11.23 remains to be elucidated. Several
genes within the 7q11.23 region that have been shown to be
associated with chromatin remodeling may provide clues [9–11].
Notably, WBSCR22 (also known as BUD23), containing a methyl-
transferase domain, is thought to act on DNA methylation [10].
Therefore, it is possible that the loss of these genes could trigger in
an epigenetic imbalance in WS, especially as histone modifications
interact with DNA methylation to modify chromatin remodeling.
Social behavior is essential for human and animal well-being, and
is mediated by multiple brain regions such as the medial PFC,
amygdala, and superior temporal sulcus [2]. Of these, the first is
generally thought to be related to social information processing and
integration, whereas the last mediates social cognition including the
perception of faces and human emotion [39, 40]. Interestingly, brain
imaging has shown that abnormal PFC activity, including that in the
orbitofrontal cortex, is linked to hypersociability in WS patients [41].
Further challenges of WS remain to reveal the relationships between
DNA methylation and brain activity on imaging.
Our study has several limitations. As WS is rare, high-quality
age- and sex-matched brain and other tissues are difficult to
collect, and thus, surveys are based solely on peripheral blood.
Here we analyzed blood samples from age- and sex-balanced
Japanese subjects. However, a potential bias should be
considered, as adolescent individuals were included in the WS
patient group but do not in the controls, and the effects of
genetic background/ancestry were not examined. Further, other
important factors might be undetectable in our survey due to
the limited coverage of CpG sites in the genome on the Illumina
450K array. Accordingly, methyl-seq might prove informative in
the future, especially if costs are further reduced. Last, we used
the SRS-2 based on a parental/caregiver questionnaire, which is
widely used as an efficient quantitative measure of the various
dimensions of social behavior [15]. Our results demonstrated
that WS patients have mild–moderate impairments in social
functioning, according to this metric. These results were
consistent with a previous clinical study [42]. However, as
patients have intellectual disability, they could not complete the
tests by themselves. Therefore, we had no choice but to
evaluate their behavior from mixed datasets, by self-assessment
(for control subjects) and by parental-assessment (for patients).
To our knowledge, this is the largest survey of DNA methylation
in WS. Altered methylation patterns in blood samples were
observed to converge on several disease-specific modules.
Although the present study provides novel evidence regarding
epigenetic imbalances based on DNA methylation and gene
dysregulation in WS, further mechanistic studies are required to
fully understand how these epigenetic alterations lead to complex
behavioral phenotypes.
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